The Effect of Probiotics on Gut Microbiotain After Helicobacter Pylori Eradication
Launched by NANJING FIRST HOSPITAL, NANJING MEDICAL UNIVERSITY · Dec 17, 2022
Trial Information
Current as of February 05, 2025
Unknown status
Keywords
ClinConnect Summary
After being informed about the study and potential risks, all patients giving written informed consent will undergo a 1-week screening period to determine eligibility for study entry. At week 0, patients who meet the eligibility requirement will be included in this simultaneous blind test. A total of 100 patients with HP infection were enrolled in this study. All patients were randomly divided into two groups according to the ratio of 1:1. Group A was given vonoprazan 20mg bid, amoxicillin 1000mg tid, Probiotics 3tabltes tid for 14 consecutive days; Group B was given vonoprazan 20mg bid and...
Gender
ALL
Eligibility criteria
- Inclusion Criteria:
- • 1. Ages between 18 and 65 years; Sexes eligible for study: both;
- • 2. patients who are diagnosed with Helicobacter pylori;
- • 3. treatment-naive patients or patients who failed to eradicate Helicobacter pylori in the past but haven't undergone eradication therapy in the past six months;
- • 4. voluntary to be involved in the study and written informed consent was obtained from all patients
- Exclusion Criteria:
- • 1. allergic reactions to the study drugs;
- • 2. patients with peptic ulcer;
- • 3. patients who underwent eradication therapy for Helicobacter pylori during the last six months;
- • 4. patients who took antibiotics,bismuth agents,probiotics within four weeks prior to treatment and those who took H2 receptor antagonists,proton pump inhibitors(PPIs) or potassium competitive acid blockers within two weeks prior to treatment;
- • 5. patients who are taking glucocorticoids, non-steroidal anti-inflammatory drugs or anticoagulants;
- • 6. patients who have history of esophageal or gastric surgery;
- • 7. pregnant or lactating women;
- • 8. patients who have severe concurrent diseases such as hepatic,cardiovascular,respiratory,renal disorders or malignancies;
- • 9. Alcohol abusers
Trial Officials
Zhenyu Zhang
Study Chair
Nanjing First Hospital, Nanjing Medical University
About Nanjing First Hospital, Nanjing Medical University
Nanjing First Hospital, affiliated with Nanjing Medical University, is a leading medical institution dedicated to advancing healthcare through innovative research and clinical trials. With a strong emphasis on patient-centered care and cutting-edge medical practices, the hospital serves as a key player in the development of new therapies and treatment protocols. Its collaborative environment fosters interdisciplinary research, enabling the integration of scientific inquiry with clinical application. Nanjing First Hospital is committed to improving health outcomes and contributing to the global medical community through rigorous trial design and execution, ensuring the highest standards of ethical practice and patient safety.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Nanjing, Jiangsu, China
People applied
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported
Discussion 0
Similar Trials